Imedex: Education is the Best Medicine®

Register for an upcoming conference!

Phone: +1 (678) 242 0906
registration@imedex.com

Perspectives in Melanoma XIII

October 8-10, 2009

Baltimore, Maryland

Renaissance Harborplace Baltimore Hotel

Continuing Medical Education

ACCME

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex designates this educational activity for AMA PRA Category 1 Credit^TM.

Who Should Attend

This educational activity is specifically designed for medical and surgical oncologists, dermatologists, and other physicians, physicians-in-training, and researchers interested and/or involved in the treatment of patients with melanoma and associated complications.

Objectives

Upon completion of this educational activity, attendees should be able to:

Discuss important aspects of the biology, pathogenesis and epidemiology of melanoma
Evaluate emerging technologies for biomarker identification and the potential impact of biomarkers on treatment and management of melanoma
Integrate important advances in diagnostic and imaging methodologies into clinical practice
Describe emerging concepts and progress in the role of surgery and staging of melanoma
Explain the role of the immune system in melanoma pathogenesis and identify immunological targets for therapy
Evaluate the therapeutic benefit from immunotherapeutic strategies such as anti–CTLA-4 monoclonal antibodies and Toll-like receptor agonists based on their effect on the signaling pathways involved in T-cell regulation and activation
Analyze recent progress in melanoma vaccine development
Discuss the molecular biology and therapeutic potential of targeting signal transduction pathways involved in the pathogenesis of melanoma, such as the MAPK and PI3K pathways, as well as mediators of angiogenesis
Recommend appropriate strategies for therapeutic intervention in patients with metastatic melanoma

Charles Balch, MD, FACS
Johns Hopkins Institute for Clinical and Translational Research
Baltimore, Maryland

Marcus Bosenberg, MD
Yale University School of Medicine
New Haven, Connecticut

Clara Curiel-Lewandrowski, MD
University of Arizona
Tucson, Arizona

Soheil Sam Dadras MD, PhD
Stanford University School of Medicine
Stanford, California

Alexander M.M. Eggermont, MD, PhD
Erasmus University Medical Center
Daniel Den Hoed Cancer Center
Rotterdam, The Netherlands

Keith T. Flaherty, MD
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Thomas Gajewski, MD, PhD
University of Chicago
Chicago, Illinois

Jeffrey E. Gershenwald, MD
University of Texas
MD Anderson Cancer Center
Houston, Texas

Allan C. Halpern, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

F. Stephen Hodi, MD
Dana-Farber Cancer Institute
Boston, Massachusetts

Mohammed Kashani-Sabet, MD
University of California at San Francisco
San Francisco, California

Kevin B. Kim, MD
University of Texas
MD Anderson Cancer Center
Houston, Texas

John M. Kirkwood, MD
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

David H. Lawson, MD
Emory University School of Medicine
Atlanta, Georgia

Sancy A. Leachman, MD, PhD
The University of Utah School of Medicine
Salt Lake City, Utah

Kerrington Molhoek, MD
University of Virginia
Charlottesville, Virginia

Stergios Moschos, MD
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Steven J. O'Day, MD
The Angeles Clinic and Research Institute
Santa Monica, California

Ben Ho Park, MD, PhD
Johns Hopkins University School of Medicine
Baltimore, Maryland

Igor Puzanov, MD
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Craig L. Slingluff, Jr., MD
University of Virginia
Charlottesville, Virginia

Susan M. Swetter, MD
Stanford University Medical Center
Stanford, California

Ahmad Tarhini, MD, MSc
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Hussein Tawbi, MD
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Suzanne Topalian, MD
Johns Hopkins University
Baltimore, Maryland

George Xu, MD, PhD
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

Hassane Zarour, MD
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Thursday, October 8, 2009

8:30 am
Welcome Address
John M. Kirkwood, MD

Session I: Epidemiology, genetics, and prevention
Moderator: Susan M. Swetter, MD

8:45 am
Increasing burden of melanoma in young women: What’s really going on?
Speaker invited

9:05 am
Differential effects of UVA and UVB radiation: Moles versus malignancy
Speaker invited

9:30 am
Current understanding of the genetics of melanoma
Sancy A. Leachman, MD, PhD

9:55 am
The role of p16 testing in patients at high-risk for melanoma
Sancy A. Leachman, MD, PhD

10:15 am
Does regular use of NSAIDs protect against melanoma? Updates on chemoprevention in melanoma
Clara Curiel-Lewandrowski, MD

10:40 am
Panel discussion

10:50 am
Break

Session II: Detection and prognosis
Moderator: John M. Kirkwood, MD

11:10 am
Optical imaging and diagnosis of melanoma: Where we are today and where we may be tomorrow
Allan C. Halpern, MD

11:40 am
Molecular diagnosis of melanoma
Mohammed Kashani-Sabet, MD

12:05 pm
Prognostic significance of lymphatic invasion in primary melanomas
George Xu, MD, PhD

12:25 pm
Panel discussion

12:35 pm
Lunch

Session III: Abstract session I

1:45 pm
Oral presentation of selected abstracts

2:45 pm
Break

Session IV: Surgery and staging

3:05 pm
The new AJCC staging system
Charles Balch, MD, FACS

3:25 pm
The lymphovascular compartment, and its assessment with miRNA technology
Soheil Sam Dadras MD, PhD

3:45 pm
Panel discussion

4:00 pm
Adjourn

Friday, October 9, 2009

8:30 am
Introduction to day two

Session V: Immunomodulation

8:40 am
Molecular insights upon toll-like receptor agonists and vaccination in melanoma
Hassane Zarour, MD

9:00 am
Tumor localization of T-cells
Thomas Gajewski, MD, PhD

9:20 am
Current status of PD-1 interventions for melanoma and other solid tumors
Suzanne Topalian, MD

9:40 am
GM-CSF as an immunologic adjuvant in human cancer vaccines
Craig L. Slingluff, Jr., MD

10:00 am Panel discussion

10:15 am
Break

Session VI: Abstract Session II

10:45 am
Oral presentation of selected abstracts

11:45 am
Lunch

1:00 pm
Special address to the melanoma community
Valerie Guild, The Aim at Melanoma Foundation

Friday, October 9, 2009 (cont'd)

Session VII: Emerging molecular targets in melanoma
Moderator: Keith Flaherty, MD

1:20 pm
Mouse model(s) to guide drug development/discovery of novel therapeutic targets
Marcus Bosenberg, MD

1:40 pm
Targeting C-Kit in celanoma — DFCI experience and overview of current trials
F. Stephen Hodi, MD

2:00 pm
Therapeutic targeting of the MAP kinase pathway in melanoma
Igor Puzanov, MD

2:20 pm
Break

2:40 pm
Options to target the PI3K pathway for therapy of melanoma
Ben Ho Park, MD, PhD

3:00 pm
CDK inhibitors—rationale and prospects for future therapeutic intervention
Stergios Moschos, MD

3:20 pm
Targeting angiogenesis with VEGF TRAP in melanoma (results of a CCC phase II trial)
Ahmad Tarhini, MD, MSc

3:40 pm
The potential of combinations of agents for targeted therapy of melanoma
Kerrington Molhoek, MD

4:00 pm
Panel discussion

4:15 pm
Adjourn

Saturday, October 10, 2009

8:30 am
Introduction to day three

Session VIII: Special topics in melanoma

8:40 am
Drug resistance and its abrogation
Hussein Tawbi, MD

9:00 am
Molecular analysis of resistance to non-classical aklylators: New options for improved cytotoxic therapy of melanoma
Speaker invited

9:20 am
Management of site-specific metastasis
Jeffrey E. Gershenwald, MD

9:40 am
Break

Session IX: Abstract Session III

10:00 am
Oral presentation of selected abstracts

Session X: Clinical trial updates

11:00 am
E4697
David H. Lawson, MD

11:20 am
SYMMETRY
Steven J. O'Day, MD

11:40 am
E2603
Keith T. Flaherty, MD

12:00 pm
BEAM
Kevin B. Kim, MD

12:20 pm
Discussion

12:30 pm
Adjourn

Participants interested in presenting data should submit abstracts online at www.imedex.com by August 17, 2009. Abstracts are subject to acceptance by the Scientific Committee. Once accepted, abstracts will be published in the final course book and scheduled for oral or poster presentation.

Acceptance notifications and guidelines for poster presentation will be sent on September 7, 2009. Authors of accepted abstracts who have not registered will have until September 24, 2009 to do so at the rate of $299.00. After this date, abstracts without registered presenters will be disregarded.

Submit your abstract online by going to www.imedex.com, selecting this Congress and following the instructions in the “Abstracts” section.

Abstract Guidelines

Follow the online instructions
Abstracts must be written in English
Accepted format: Word document format, 9 point Arial font, 500 word count limit
Use a concise title
List affiliations of author(s) as briefly as possible, with city, state and country
Place an asterisk (*) before the name of the presenting author
Use standard and well-accepted abbreviations
When using references, use standard and well-accepted formats
Abstract content should be single-spaced, typed in lower case and contain:
- Purpose of the study
- Summarized description of the project
- Results and conclusions

Submission Deadline

August 17, 2009

REGISTRATION FEES

Discounted.................................... $299
If payment received by August 6, 2009

Regular...........................................$399
If payment received by October 1, 2009

Full/Onsite......................................$499
If payment received after October 1, 2009

Group discount (physicians only)*..-$50
*cannot be combined with any other discounts

Nurses/Students/Residents *........$199
*proof of eligibility must accompany registration

To Register:

You may register online by October 1, 2009 at www.imedex.com, or by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Group Discounts:

Each one of multiple registrants from the same institute or practice each receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician. Group discount cannot be combined the Nurses/Students/Residents rate.

Payment:

To pre-register, registration and payment must be received no later than October 1, 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.

Registration Fee Inclusions:

Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.

Cancellation:

For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than October 1, 2009. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after October 1, 2009.

Renaissance Harborplace Baltimore Hotel
202 East Pratt Street
Baltimore, Maryland 21202
Tel.: +1 (410) 547 1200
Fax: +1 (410) 539 5780
Renaissancehotels.com/bwish

The Renaissance Harborplace Baltimore Hotel is delighted to showcase a new distinctive design featuring modern urban sophistication. The hotel is situated just steps from the area's most unique sights and attractions. Enjoy premier access to the world-famous Inner Harbor - home to the Baltimore Aquarium, the Maryland Science Center. The Renaissance Baltimore hotel's WATERTABLE restaurant/lounge and Ground Floor Café have become local favorites, boasting award-winning culinary talent and offering an all-natural menu bringing stylish twists to each season's finest ingredients. Refresh in comfortable yet refined environs at the Renaissance hotel in Baltimore Inner Harbor. Experience the rich culture of Charm City, in a vibrant location sure to delight you, at this Baltimore Inner Harbor hotel.

For the convenience of attendees, a limited number of rooms have been reserved until September 16, 2009 at a discounted rate of $199.00 for single or double occupancy, plus tax, currently at 13.5%. This rate is not guaranteed outside the conference dates or after September 16, 2009. To reserve your room please contact the Renaissance Harborplace Baltimore Hotel reservations department at +1 800 Hotels-1 (+1 (800) 468-3571. To receive the group rate, callers must identify themselves as being with the Imedex USA block or use the market code DEXC. You may also visit the hotel’s website at www.renaissanceharborplace.com. Internet users must enter the meeting promotional code: DEXDEXA. Reservation requests received after September 16, 2009 may not be guaranteed the group rate.

Dear Colleague,

It is with great pleasure that we invite you to join us for Perspectives in Melanoma XIII. This fall’s conference, October 8-10, 2009 in Baltimore, Maryland, promises to be an outstanding educational event!

Perspectives in Melanoma XIII has become a premier forum for discussion on the latest advances in melanoma research and emerging therapies. With an interactive and exciting scientific agenda planned, this conference provides an overview of the most current and controversial topics in the field of melanoma.

With 12 years of exceptional educational value, this conference remains a forum to update your knowledge in the field, confirm your current practices and receive valuable take-home information on exciting new screening and staging modalities, management approaches, emerging treatment options and clinical trial updates. Providing an overview of recent advances, Perspectives in Melanoma XIII is led by renowned thought leaders and current investigators in melanoma; this conference will expand several of the most promising new leads from the bench to the clinic.

Over 200 physicians, researchers, nurses other healthcare professionals attended Perspectives in Melanoma XI in 2007 in California and nearly 400 attended last year in The Netherlands. Attendees of both value the scope and depth of the information on disease biology, management, and research presented.

Additionally, the valuable opportunity to interact with colleagues and learn from key thought leaders in melanoma, as well as network with the diverse mix of oncologists, surgeons, dermatologists and researchers who attend, is immeasurable.

We look forward to seeing you for what is sure to be a rewarding and dynamic experience; your diverse perspectives and contributions add immeasurable value to this educational and interactive conference!

Sincerely,

John M. Kirkwood, MD, Chair
Alexander M.M. Eggermont, MD, PhD, Chair

Keith T. Flaherty, MD, Co-Chair
Craig L. Slinghuff, Jr., MD, Co-Chair
Susan Swetter, MD, Co-Chair

Conference Location and Registration

Renaissance Harborplace Baltimore Hotel
202 East Pratt Street
Baltimore, Maryland 21202
Tel.: +1 (410) 547 1200
Fax: +1 (410) 539 5780
Renaissancehotels.com/bwish

The Registration and Information Desk will be staffed:

Thursday, October 8, 2009
7:30 am – 4:20 pm

Friday, October 9, 2009
8:00 am – 4:40 pm

Saturday, October 10, 2009
8:00 am – 12:30 pm

Endorsing Societies:

Chairs:

John M. Kirkwood, MD
University of Pittsburgh Medical Center
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States

Alexander M.M. Eggermont, MD, PhD
Erasmus University Medical Center
Daniel Den Hoed Cancer Center
Rotterdam, The Netherlands

Co-Chairs:

Keith T. Flaherty, MD
Massachusetts General Hospital
Cancer Center
Boston, Massachusetts

Craig L. Slingluff, Jr., MD
University of Virginia
Charlottesville, Virginia

Susan M. Swetter, MD
Stanford School of Medicine
Stanford University Medical Center
Stanford, California

Organizer:

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

Comments from your collegues:

"Hard to improve perfection"
"All speakers were excellent – Drs. Kirkwood and Eggermont did an excellent job"
"Everything was excellent and well organized"

Important Dates

Discounted Registration Deadline
August 6, 2009

Abstract Submission Deadline
August 17, 2009

Abstract Notifications Mailed
September 7, 2009

Abstract Presenter Registration Deadline
September 24, 2009

Regular Registration Deadline
October 1, 2009

Presentation Dates
October 8-10, 2009

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

The following companies have provided an educational grant in support of this conference:

PLATINUM

SILVER

GSK

BRONZE

Lilly

CORPORATE

Abbott

Several options are available to companies interested in supporting this Congress.
For more information, please contact Imedex at +1(770) 751 7332, or by email at cme@imedex.com.

The following companies are an exhibitor at this conference:

Elsevier

GSK

Opportunities are available to companies interested in exhibiting at this conference.
For more information, please contact Cori Gunter at +1(678) 242 0712, or by email at c.gunter@imedex.com.